Pivotal Bio Venture Partners Investment Advisor LLC Trevi Therapeutics, Inc. Transaction History
Pivotal Bio Venture Partners Investment Advisor LLC
- $111 Million
- Q3 2025
A detailed history of Pivotal Bio Venture Partners Investment Advisor LLC transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, Pivotal Bio Venture Partners Investment Advisor LLC holds 1,256,782 shares of TRVI stock, worth $14.2 Million. This represents 10.15% of its overall portfolio holdings.
Number of Shares
1,256,782
Previous 1,146,110
9.66%
Holding current value
$14.2 Million
Previous $6.27 Million
79.22%
% of portfolio
10.15%
Previous 5.92%
Shares
2 transactions
Others Institutions Holding TRVI
# of Institutions
173Shares Held
119MCall Options Held
629KPut Options Held
1.22M-
Nea Management Company, LLC Timonium, MD13.2MShares$150 Million7.39% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.3MShares$116 Million3.88% of portfolio
-
Rubric Capital Management LP New York, NY8.53MShares$96.7 Million1.25% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.83MShares$66 Million0.0% of portfolio
-
Viking Global Investors LP5.13MShares$58.1 Million0.13% of portfolio
About Trevi Therapeutics, Inc.
- Ticker TRVI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,322,500
- Market Cap $661M
- Description
- Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...